Skip to main content

Market Overview

ThermoGenesis Cord Blood Processing System Wins Health Canada Approval


Cesca Therapeutics (NASDAQ: KOOL) shares spiked higher after the company's subsidiary, ThermoGenesis, received Health Canada approval for its AXP II System for cord blood processing.

"Health Canada's approval of the AXP II -- following its approval of the PXP System earlier this year -- marks the achievement of yet another key milestone and should allow us to meaningfully expand our footprint with a best-in-class system that, today, continues to hold a market-leading position,’ said Haihong Zhu, President of ThermoGenesis.

“We look forward to building on our customer base by offering Cord Blood Banks throughout Canada with the ability to undertake cord blood processing with a system that generates mononuclear cell recoveries of >90% and CD34+ stem and progenitor cell recoveries of > 95%," said Zhu.

Cesca Therapeutics shares were trading higher by 8.6% to $3.08 Tuesday morning. The stock opened the session at $3.82 per share.

Related Links:

PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation

Pfizer To Buy Array Pharma For $48/Share


Related Articles (KOOL)

View Comments and Join the Discussion!

Posted-In: Health Canada ThermoGenesisNews Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at